Calliditas Therapeutics Ab (CLTEF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Calliditas Therapeutics Ab (CLTEF) trades at $0.06 with AI Score 45/100 (Grade C). Calliditas Therapeutics Ab (CLTEF) is a biopharmaceutical company focused on developing treatments for autoimmune and rare diseases, particularly kidney disorders. Market cap: $3.60M, Sector: Technology.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CLTEF: CLTEF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CLTEF against Technology peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CLTEF: the 1 perspectives are evenly split.
How is this calculated? →Calliditas Therapeutics Ab (CLTEF) Technology Profile & Competitive Position
Calliditas Therapeutics Ab (CLTEF) operates within the biopharmaceutical sector, specializing in innovative treatments for autoimmune diseases, leveraging its FDA-approved TARPEYO product to target unmet medical needs in kidney disorders.
What Is the Investment Thesis for CLTEF?
Calliditas Therapeutics Ab presents a unique investment thesis anchored by its FDA-approved TARPEYO product, which addresses a significant medical need in the treatment of IgAN. With a market cap of $3.60M and a profit margin of -38.6%, the company is in a critical phase of scaling its operations and achieving profitability. The ongoing commercialization of TARPEYO is expected to drive revenue growth, especially as awareness of IgAN increases among healthcare providers and patients. Additionally, the company’s high gross margin of 93.6% suggests strong pricing power and potential for substantial profit generation as sales increase. However, investors should remain cautious of the liquidity and volatility risks associated with trading on the OTC market, as well as the company’s cash burn rate and the necessity for ongoing funding to support its operations and R&D efforts. Monitoring sales performance and any regulatory developments will be essential for assessing the company’s trajectory and market viability.
Based on FMP financials and quantitative analysis
CLTEF Key Highlights
- Market cap of $3.60M indicates a small but focused biopharmaceutical company.
- Gross margin of 93.6% highlights strong potential profitability as sales increase.
- Profit margin of -38.6% reflects current operational challenges but potential for improvement.
- FDA approval of TARPEYO establishes a revenue-generating product in a niche market.
- Beta of -1.41 suggests significant volatility, typical for OTC traded stocks.
Who Are CLTEF's Competitors?
CLTEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| NOW ServiceNow, Inc. | $108.69 | +2.23% | $112.09B | 71 |
| RSASF RESAAS Services Inc. | $0.30 | +2.76% | $25.04M | 69 |
| CSAI Cloudastructure Inc. | $0.36 | +0.47% | $6.84M | 68 |
| PDFS PDF Solutions, Inc. | $56.75 | -4.11% | $2.34B | 68 |
| USER UserTesting, Inc. | $7.50 | -0.13% | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLTEF's Key Strengths?
- FDA-approved product in TARPEYO, providing a revenue stream.
- High gross margin indicating potential for profitability.
- Strong focus on niche markets with unmet medical needs.
What Are CLTEF's Weaknesses?
- Small market capitalization leading to liquidity risks.
- Negative profit margin indicating current operational challenges.
- Dependence on a single product for revenue generation.
What Could Drive CLTEF Stock Higher?
- Potential expansion of TARPEYO into new indications.
- Commercialization efforts for TARPEYO in the U.S. market.
- Possible strategic partnerships to enhance distribution capabilities.
- Research and development initiatives to support product pipeline.
What Are the Key Risks for CLTEF?
- Negative return on equity (-84.7%) — the business is not currently generating profit on shareholder capital.
- Regulatory challenges in expanding product indications.
- Market volatility due to OTC trading conditions.
- Competition from larger pharmaceutical companies with established products.
- Dependence on a single product for revenue generation.
What Are the Growth Opportunities for CLTEF?
- Expansion of TARPEYO's market presence: With the FDA approval of TARPEYO, Calliditas has the opportunity to capture a significant share of the IgAN treatment market, which is expected to grow as awareness and diagnosis of the disease increase. The global market for IgAN treatments is projected to reach approximately $1 billion by 2028, providing a substantial revenue opportunity for the company.
- Development of additional indications for TARPEYO: Calliditas is exploring the potential for TARPEYO to be used in other related kidney disorders, which could expand its market reach and enhance revenue streams. If successful, this could significantly increase the patient population eligible for treatment, further driving sales growth.
- Strategic partnerships and collaborations: The company may seek partnerships with larger pharmaceutical firms to leverage their distribution networks and marketing expertise. Such alliances could facilitate faster market entry and broader access to healthcare providers, enhancing TARPEYO's visibility and adoption.
- Investment in research and development: Continued investment in R&D will be crucial for Calliditas to innovate and develop new therapies. By focusing on rare diseases with high unmet needs, the company can position itself as a leader in niche markets, potentially attracting interest from investors and partners.
- Geographic expansion: Calliditas may consider expanding its operations into new markets, particularly in regions with high prevalence rates of autoimmune diseases. This could involve regulatory approvals and market entry strategies tailored to specific regions, providing new revenue opportunities.
What Opportunities Does CLTEF Have?
- Expansion into new geographic markets.
- Development of additional indications for TARPEYO.
- Strategic partnerships to enhance market reach.
What Threats Does CLTEF Face?
- Intense competition from established pharmaceutical companies.
- Regulatory challenges in new markets.
- Market volatility due to trading on the OTC platform.
What Are CLTEF's Competitive Advantages?
- FDA approval of TARPEYO provides a significant competitive advantage.
- High gross margin indicates strong pricing power and profitability potential.
- Focus on niche markets reduces direct competition.
- Expertise in autoimmune diseases enhances credibility and market positioning.
- Strong R&D capabilities support innovation and product development.
What Does CLTEF Do?
Founded on April 15, 2021, Calliditas Therapeutics Ab is a biopharmaceutical company headquartered in Richmond, Canada. The firm is dedicated to developing and commercializing innovative therapies for patients suffering from autoimmune and rare diseases. Its primary focus is on kidney disorders, where it aims to address significant unmet medical needs. The company's flagship product, TARPEYO (budesonide) delayed-release capsules, has received FDA approval for the treatment of primary IgA nephropathy (IgAN), a progressive kidney disease characterized by the accumulation of IgA antibodies in the kidneys, leading to proteinuria and potential kidney failure. With a gross margin of 93.6%, Calliditas Therapeutics demonstrates a strong capacity for profitability once sales scale up. The company operates in a competitive landscape, facing challenges from both established pharmaceutical companies and emerging biotech firms. Despite its small market capitalization of $3.60M, Calliditas is strategically positioned to capitalize on the growing demand for specialized treatments in the autoimmune disease space. The company’s commitment to research and development is evident in its ongoing efforts to expand its product pipeline and explore additional indications for TARPEYO, which could further enhance its market position and revenue potential.
What Products and Services Does CLTEF Offer?
- Develops and commercializes treatments for autoimmune diseases.
- Focuses primarily on kidney disorders, particularly IgAN.
- Offers TARPEYO, an FDA-approved medication for proteinuria reduction.
- Engages in research and development to expand its product pipeline.
- Provides professional services to guide clients in effective product utilization.
- Operates primarily within the biopharmaceutical sector.
How Does CLTEF Make Money?
- Generates revenue through the sale of TARPEYO to healthcare providers.
- Engages in partnerships for research and development funding.
- Explores additional indications for existing products to broaden market reach.
- Utilizes professional services to enhance client engagement and satisfaction.
- Focuses on high-margin products to maximize profitability.
What Industry Does CLTEF Operate In?
The biopharmaceutical industry is characterized by rapid innovation and a strong focus on developing targeted therapies for complex diseases. The global market for autoimmune disease treatments is projected to grow significantly, driven by increasing prevalence and awareness of these conditions. Calliditas Therapeutics operates within this expanding market, specifically targeting kidney disorders, which represent a critical area of unmet medical need. The competitive landscape includes both established pharmaceutical giants and emerging biotech firms, necessitating ongoing innovation and strategic positioning to capture market share.
Who Are CLTEF's Key Customers?
- Healthcare providers treating patients with autoimmune diseases.
- Pharmaceutical distributors and wholesalers.
- Patients diagnosed with IgAN and related kidney disorders.
- Research institutions involved in autoimmune disease studies.
- Investors interested in biopharmaceutical innovations.
Company Profile
Calliditas Therapeutics Ab operates in the Software - Application industry within the Technology sector. It is headquartered in Richmond, SE. The company is led by CEO Jonah Hicks. CLTEF has traded publicly since 2025.
How Calliditas Therapeutics Ab Is Valued
Calliditas Therapeutics Ab carries a market capitalization of $3.60M, placing it in the micro-cap category. Relative to its peer group, CLTEF's quantitative score of 45/100 is below the peer average of 81/100.
ROE -85%Key Financial Metrics
Return on equity for Calliditas Therapeutics Ab stands at -84.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -24.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.2%, the inverse of the P/E and a quick read on earnings relative to price.
CLTEF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Calliditas seems to be gaining traction in the social trading sphere; more users are discussing it positively, suggesting growing awareness and confidence in the company's direction.
- Recent insider moves might indicate strong internal belief in the company's future prospects, which is often a good sign for long-term investors.
- The community buzz suggests a growing narrative around Calliditas potentially becoming a key player in its niche, driving increased interest and investment.
- Market perception seems to be shifting positively, with more discussions focusing on potential catalysts and less on risks, which could attract more investors.
Bear Case
- Despite positive chatter, some community members are expressing concern about the company's competitive landscape, questioning its ability to maintain a leading position.
- There's a lingering skepticism among some traders about whether Calliditas can truly deliver on its promises, leading to hesitation in fully embracing a bullish stance.
- The overall market sentiment, while improving, still has pockets of bearish views, particularly regarding the broader healthcare sector's vulnerability to regulatory changes.
- Some community members are pointing out potential risks associated with the company's long-term growth strategy, suggesting that it might be too ambitious or capital-intensive.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
CLTEF Latest News
No recent news available for CLTEF.
CLTEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLTEF.
Price Targets
Wall Street price target analysis for CLTEF.
CLTEF MoonshotScore
What does this score mean?
The MoonshotScore rates CLTEF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jonah Hicks
CEO
Jonah Hicks has a robust background in the biopharmaceutical sector, with extensive experience in product development and commercialization. He holds a degree in Pharmaceutical Sciences and has previously worked in various leadership roles across notable biotech firms, focusing on innovative treatment solutions for complex diseases.
Track Record: Under his leadership, Calliditas Therapeutics has successfully obtained FDA approval for TARPEYO and has laid the groundwork for future product development and market expansion.
CLTEF OTC Market Information
The OTC Other tier includes companies that may not meet the financial standards for listing on major exchanges like NYSE or NASDAQ. These stocks often have less stringent reporting requirements, which can lead to increased risk and volatility for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial reporting may obscure the company's true financial health.
- Potential for high volatility due to low trading volume.
- Regulatory risks associated with drug approvals and market entry.
- Review recent financial statements and disclosures.
- Assess the company's cash burn rate and funding needs.
- Monitor sales performance of TARPEYO and market reception.
- Investigate any ongoing clinical trials or product developments.
- Evaluate competitive landscape and market positioning.
- FDA approval of TARPEYO enhances credibility.
- Established leadership team with relevant industry experience.
- Presence of partnerships or collaborations with reputable firms.
CLTEF Technology Stock FAQ
What does Calliditas Therapeutics Ab do?
Calliditas Therapeutics Ab specializes in developing and commercializing innovative treatments for autoimmune diseases, with a primary focus on kidney disorders. Its flagship product, TARPEYO, is FDA-approved for reducing proteinuria in adults with primary IgAN, addressing a significant unmet medical need in this niche market.
What are the main risks for CLTEF?
Calliditas Therapeutics faces several risks, including regulatory challenges in expanding TARPEYO's indications and potential competition from larger pharmaceutical companies. Additionally, the company's small market capitalization and trading on the OTC market expose it to liquidity risks and market volatility.
How does Calliditas Therapeutics Ab invest in research and development?
Calliditas Therapeutics Ab allocates a portion of its budget to research and development, focusing on innovative treatments for autoimmune diseases. The company's R&D efforts are critical for expanding its product pipeline and exploring additional indications for TARPEYO, which could enhance its market position and revenue streams.
What are the key factors to evaluate for CLTEF?
Calliditas Therapeutics Ab (CLTEF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does CLTEF data refresh on this page?
CLTEF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CLTEF's recent stock price performance?
Calliditas Therapeutics Ab (CLTEF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: FDA-approved product in TARPEYO, providing a revenue stream. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLTEF overvalued or undervalued right now?
Valuing Calliditas Therapeutics Ab (CLTEF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CLTEF?
Before investing in Calliditas Therapeutics Ab (CLTEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available due to OTC classification.